Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
7X Partners acquires 40% of Leventer Medical to back €25m private oncology hospital in Bucharest
7X Partners acquires 40% of Leventer Medical to back €25m private oncology hospital in Bucharest Romanian private equity firm 7X Partners has acquired a 40% stake in Leventer Medical to support the development of a private oncology hospital in Bucharest, marking a...
Coller Capital raises $2.4bn in record structured secondaries deal backed by Barings and Ares
Coller Capital raises $2.4bn in record structured secondaries deal backed by Barings and Ares Coller Capital has closed a landmark $2.4bn structured secondaries transaction, marking the largest deal of its kind to date in the secondaries market. The vehicle has...
Brookfield to take up to 80% stake in Barclays payments business under £400m strategic partnership
Brookfield to take up to 80% stake in Barclays payments business under £400m strategic partnership Brookfield Asset Management entered into a long-term partnership with Barclays to transform the UK bank’s payment acceptance business, with plans to take a controlling...